Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 115-118

  Johnsson, Hanna J ^a   McInnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Interleukin 23; Psoriasis; Psoriatic arthritis; Ustekinumab

Indexed keywords

ETANERCEPT; GUSELKUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; METHOTREXATE; PLACEBO; TILDRAKIZUMAB; USTEKINUMAB; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL PRODUCT;

ARTHRALGIA; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE DESTRUCTION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DACTYLITIS; DAS28; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTHESITIS; GENETIC ASSOCIATION; HEADACHE; HEART DISEASE; HUMAN; INFECTION; NEOPLASM; OSTEOCLAST ACTIVITY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RHINOPHARYNGITIS; SPONDYLARTHRITIS; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; DRUG EFFECTS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; REMISSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-12; INTERLEUKIN-23; MOLECULAR TARGETED THERAPY; REMISSION INDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84983158087     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. van den BERG WB, McINNES IB: Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013; 43: 158-70.
2. IWAKURA Y, NAKAE S, SAIJO S, ISHIGAME H: The roles of IL-17A in inflammatory immune responses and host defence against pathogens. Immunol Rev. 2008; 226: 57-79.
3. MIOSSEC P, KORN T, KUCHROO VK: Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
4. O'RIELLY DD, RAHMAN P: Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol 2014; 28: 673-85.
5. YAWALKAR N, KARLEN S, HUNGER R, BRAND CU, BRAATHEN LR: Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998; 111: 1053-7.
6. LEE E, TREPICCHIO WL, OESTREICHER JL et al.: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
7. PISKIN G, SYLVA-STEENLAND RM, BOS JD, TEUNISSEN MB: In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908-15.
8. CELIS R, PLANELL N, FERNáNDEZ-SUEIRO JL et al.: Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012; 14: R93.
9. MENG Y, DONGMEI L, YANBIN P et al.: Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol 2014; 39: 696-707.
10. LEONARDI CL, KIMBALL AB, PAPP KA et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
11. PAPP KA, LANGLEY RG, LEBWOHL M et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
12. GRIFFITHS CE, STROBER BE, van de KERKHOF P et al.: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
13. PAPP KA, GRIFFITHS CE, GORDON K et al.: Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-54.
14. SOFEN H, SMITH S, MATHESON RT et al.: Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133: 1032-40.
15. KOPP T, RIEDL E, BANGERT C et al.: Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015; 521: 222-6.
16. PAPP K, THAçI D, REICH K et al.: Tildrakizumab (MK-3222), an anti-IL-23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo-controlled trial. Br J Dermatol 2015 Jun 3.
17. MCINNES IB, KAVANAUGH A, GOTTLIEB AB et al.: Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-9.
18. RITCHLIN C, RAHMAN P, KAVANAUGH A et al.: Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990-9.
19. KAVANAUGH A, PUIG L, GOTTLIEB AB et al.: Efficacy and safety of ustekinumab in psoriatic arthritis patients with spondylitis and peripheral joint involvement: results from a phase 3, multicentre, double-blind, placebocontrolled study. Poster presented at: EULAR annual conference; June 10-13, 2015; Rome.
20. SATO K, SUEMATSU A, OKAMOTO K et al.: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-82.
21. KAVANAUGH A, RITCHLIN C, RAHMAN P et al.: Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73: 1000-6.
22. PAPP KA, GRIFFITHS CE, GORDON K et al.: Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis. Poster presented at: 2013 ACR/ARHP Annual Meeting; October 26-30, 2013; San Diego.
23. McINNES IB, PAPP K, PUIG L et al.: Safety of ustekinumab from the placebo-controlled periods of psoriatic arthritis and psoriasis clinical developmental programs. Poster presented at: 2013 ACR/ARHP Annual Meeting; October 26-30, 2013; San Diego.
24. MURPHY CA, LANGRISH CL, CHEN Y et al.: Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-7.
25. McINNES IB, MEASE PJ, KIRKHAM B et al.: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015 June 26. pii: S0140-6736(15)61134-5 [Epub ahead of print].